POTASSIUM PHOSPHATES Drug Patent Profile
✉ Email this page to a colleague
When do Potassium Phosphates patents expire, and when can generic versions of Potassium Phosphates launch?
Potassium Phosphates is a drug marketed by Am Regent, Amneal, Cmp Dev Llc, Fresenius Kabi Usa, and Somerset Theraps Llc. and is included in six NDAs. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in POTASSIUM PHOSPHATES is potassium phosphate, dibasic; potassium phosphate, monobasic. There are two hundred and forty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.
DrugPatentWatch® Generic Entry Outlook for Potassium Phosphates
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for POTASSIUM PHOSPHATES?
- What are the global sales for POTASSIUM PHOSPHATES?
- What is Average Wholesale Price for POTASSIUM PHOSPHATES?
Summary for POTASSIUM PHOSPHATES
International Patents: | 1 |
US Patents: | 1 |
Applicants: | 5 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 5 |
Clinical Trials: | 1 |
What excipients (inactive ingredients) are in POTASSIUM PHOSPHATES? | POTASSIUM PHOSPHATES excipients list |
DailyMed Link: | POTASSIUM PHOSPHATES at DailyMed |
Recent Clinical Trials for POTASSIUM PHOSPHATES
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mahidol University | N/A |
Pharmacology for POTASSIUM PHOSPHATES
Drug Class | Osmotic Laxative Potassium Salt |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
US Patents and Regulatory Information for POTASSIUM PHOSPHATES
POTASSIUM PHOSPHATES is protected by one US patents and two FDA Regulatory Exclusivities.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Am Regent | POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 216274-001 | Oct 2, 2023 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Cmp Dev Llc | POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 212121-001 | Sep 19, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Amneal | POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 216344-001 | Oct 10, 2023 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for POTASSIUM PHOSPHATES
See the table below for patents covering POTASSIUM PHOSPHATES around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2020081118 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for POTASSIUM PHOSPHATES
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1441735 | SPC/GB08/020 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
1499331 | 13C0055 | France | ⤷ Subscribe | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
0253310 | SPC/GB95/010 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
POTASSIUM PHOSPHATES Market Analysis and Financial Projection Experimental
More… ↓